Typical and atypical antipsychotics do not differ markedly in their reversibility of antagonism of the dopamine D2 receptor

International Journal of Neuropsychopharmacology

Volumn 17, Issue 1, 2014, Pages 149-155

  Sahlholm, Kristoffer ^a   Marcellino, Daniel ^a   Nilsson, Johanna ^a   Ögren, Sven Ove ^a   Fuxe, Kjell ^a   Århem, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotic agents; Dopamine; Dopamine antagonists; Electrophysiology

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; AMISULPRIDE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; JNJ 37822681; NEUROLEPTIC AGENT; NORCLOZAPINE; NS 30678; OLANZAPINE; POTASSIUM CHANNEL; PRECLAMOL; PRIDOPIDINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISSOCIATION; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; FEMALE; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; SOLUBILITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL PHENOMENA; CLASSIFICATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; MEMBRANE POTENTIAL; METABOLISM; OOCYTE; PHYSIOLOGY; XENOPUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MEMBRANE POTENTIALS; OOCYTES; POTASSIUM CHANNELS; RECEPTORS, DOPAMINE D2; SOLUBILITY; XENOPUS;

EID: 84888604544     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000801     Document Type: Article

References (24)

1. 2 dopamine receptors in human Y-79 retinoblastoma cells. Mol Pharmacol 39:650-658.
2. + channels. Proc Natl Acad Sci USA 100:6239-6244. (Pubitemid 36576960)
3. Carlsson ML, Carlsson A, Nilsson M (2004) Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 11:267-277. (Pubitemid 38240207)
4. 2 receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 628:19-26.
5. Gold SJ, Ni YG, Dohlman HG, Nestler EJ (1997) Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain. J Neurosci 17:8024-8037. (Pubitemid 27426238)
6. Heusler P, Newman-Tancredi A, Castro-Fernandez A, Cussac D (2007) Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. Neuropharmacology 52:1106-1113.
7. Heusler P, Newman-Tancredi A, Loock T, Cussac D (2008) Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. Eur J Pharmacol 581:37-46.
8. 2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 158:360-369. (Pubitemid 32205190)
9. Klewe IV, Nielsen SM, Tarpø L, Urizar E, Dipace C, Javitch JA, Gether U, Egebjerg J, Christensen KV (2008) Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropharmacology 54:1215-1222.
10. 2 antagonist for the treatment of schizophrenia. J Pharmacol Exp Ther 342:91-105.
11. Lester HA, Miwa JM, Srinivasan R (2012) Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects. Biol Psychiatry 72:907-915.
12. 2 receptor, application of an original filter method. J Recept Res 4:817-845. (Pubitemid 15155105)
13. 2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105:13656-13661.
14. Meltzer HY, Massey BW, Horiguchi M (2012) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13:1572-1586.
15. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17:1206-1227.
16. 2 receptors. Neuroscience 61:269-283.
17. Packeu A, Wennerberg M, Balendran A, Vauquelin G (2010) Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach. Br J Pharmacol 161:1311-1328.
18. Pettersson F, Pontén H, Waters N, Waters S, Sonesson C (2010) Synthesis and evaluation of a set of 4-phenyl-piperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). J Med Chem 53:2510-2520.
19. 2S receptor-molecular determinants and relevance to therapeutic ligands. Neuropharmacology 61:937-949.
20. 2 atypical antipsychotics. Am J Psychiatry 162:1984-1985. (Pubitemid 41428639)
21. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 156:876-884. (Pubitemid 29260342)
22. 2 receptor-mediated signaling pathways. Neuropsychopharmacology 32:67-77. (Pubitemid 44967785)
23. 4 receptor biogenesis. J Biol Chem 280:19350-19357. (Pubitemid 41379642)
24. 2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol 385:337-372.